No Association of nineteenCOX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study
1 Department of Medical Biochemistry, University of Tampere Medical School, Tampere, Finland
2 Department of Clinical Chemistry, University of Tampere and Tampere University Hospital, Tampere, Finland
3 Department of Pediatrics, University of Oulu, Oulu Finland and Department of Pediatrics, Vaasa Central Hospital, Vaasa, Finland
4 Department of Clinical Physiology, University of Kuopio, and University of Eastern Finland, Kuopio, Finland
5 FIMM, Institute for Molecular Medicine Finland, Helsinki, Finland
6 Department of Medicine, University of Turku and Turku University Hospital, Turku, Finland
7 Department of Pediatrics, University of Tampere and Tampere University Hospital, Tampere, Finland
8 Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland
9 Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku and Department of Clinical Physiology, University of Turku and Turku University Hospital, Turku, Finland
BMC Medical Genetics 2012, 13:32 doi:10.1186/1471-2350-13-32Published: 2 May 2012
The role of cyclooxygenase-2 (COX-2) single nucleotide polymorphisms has mostly been studied in relation to advanced atherosclerosis, but little is known how they contribute to preclinical disease. In the present study we analyzed whether COX-2 gene variants associate independently with the early subclinical markers of atherosclerosis, carotid intima-media thickness and carotid artery distensibility in a population of young healthy Caucasian adults.
SNPs for association analysis were collected from the COX-2 gene and 5 kb up- and downstream of it. There were 19 SNPs available for analysis, four genotyped and fifteen imputed. Genotype data was available for 2442 individuals participating in the Cardiovascular Risk in Young Finns Study. Genotype imputation was performed using MACH 1.0 and HapMap II CEU (release 22) samples as reference. Association analysis was performed using linear regression with an additive model. PLINK was used for true genotyped SNPs and ProbABEL for imputed genotype dosages. False discovery rate was used to take into account multiple testing bias.
Two of the COX-2 variants (rs689470, rs689462) associated with distensibility (p = 0.005) under the linear regression additive model. After adjustment with gender, age, body mass index and smoking status, association between these SNPs and distensibility remained significant (p = 0.031). Subjects carrying the minor alleles had higher value of carotid artery distensibility compared to the major allele homozygotes. However, after correcting p-values for multiple testing bias using false discovery rate, association was lost. Another COX-2 variant rs4648261 associated with mean carotid intima-media thickness (p = 0.046) and maximal carotid intima-media thickness (p = 0.048) in the linear regression model. Subjects carrying the minor allele of rs4648261 had lower values of mean and maximal carotid intima-media thickness compared to subjects homozygote for major allele. After adjustments the associations were lost with both mean and maximal carotid intima-media thickness. Thus, no statistically significant associations of the studied COX-2 variants with carotid artery distensibility or carotid intima-media thickness were found.
Our results suggest that in a Finnish population, there are no significant associations between COX-2 variants and early atherosclerotic changes in young adulthood.